对肿瘤网络中曲妥珠单抗辅助治疗的检测和应用的回顾——我们治疗的患者合适吗？
Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients?
机构信息
Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK.
出版信息
Clin Oncol (R Coll Radiol). 2010 May;22(4):289-93. doi: 10.1016/j.clon.2010.02.011. Epub 2010 Mar 26.
PMID:20347281
Abstract
This review of practice assessed all early breast cancer patients diagnosed over 12 months to determine the frequency of human epidermal growth factor receptor 2 (HER2) positivity and trastuzumab use. The frequency of HER2 positivity in routine practice (185/1319; 14%) was less than expected. A significant proportion of patients (56/185; 30%) did not receive trastuzumab, largely due to concerns about chemotherapy tolerability.
摘要
本实践回顾评估了所有在 12 个月内确诊的早期乳腺癌患者，以确定人类表皮生长因子受体 2（HER2）阳性和曲妥珠单抗使用的频率。常规实践中 HER2 阳性的频率（185/1319；14%）低于预期。相当一部分患者（56/185；30%）未接受曲妥珠单抗治疗，主要是由于担心化疗耐受性。
Zotero 插件